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Abstract
Purpose Preoperative chemoradiotherapy (CRT) is supposed not only to reduce lymph node metastases but also lymph
node recovery in rectal cancer specimens. The objective of this prospective study was to determine the effects of
chemoradiation on mesorectal lymph node retrieval under terms of a meticulous histopathological evaluation.
Methods Specimens from 64 consecutive patients with stage II/III rectal cancer receiving preoperative 5-FU-based CRT
were investigated. All patients were treated within the German Rectal Cancer Trial CAO/ARO/AIO-04. After surgery
(including quality assessed total mesorectal excision), extensive pathological diagnostics was performed with embedding
and microscopic evaluation of the whole mesorectal soft tissue compartment.
Results A total number of 2,021 lymph nodes were recovered (31.6 per specimen) within pathological work-up. There was no
significant correlation between the number of retrieved nodes and patient- as well as tumor-dependent parameters. Lymph node size
constantly amounted for less than 0.5 cm. Twenty patients (31.3%) had persistent nodal metastases. A considerable incidence of
residualmicrometastaticinvolvementinlymphnodes<0.3cm(in9.4%ofallpatients)wasdetectedbyextensivepathologicwork-up.
Conclusion Reliable nodal staging with high numbers of detected nodes was feasible after neoadjuvant CRT.
Micrometastases frequently occur in small lymph nodes detected by microscopic evaluation.
Keywords Locallyadvancedrectalcancer.
Preoperativechemoradiotherapy.Totalmesorectalexcision.
Pathologicdiagnostics
Introduction
Rectal cancer is the second most malignant disease in
European countries with an annual incidence of about
70,000 cases.
1,2 Distinct progress in therapy of rectal cancer
has been achieved within the last 15 years by implementation
of appropriate surgical techniques such as total mesorectal
excision (TME)
3 and neoadjuvant treatment strategies.
The German Rectal Cancer Study Group has recently
demonstrated significant improvements in local control, a
higher rate of sphincter preservation, and decreased toxicity
by preoperative in contrast to postoperative chemoradio-
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DOI 10.1007/s11605-009-1057-6therapy (CRT). A combined neoadjuvant 5-fluorouracil (5-
FU)-based CRT is thus considered as standard therapy in
locally advanced (stage II/III) rectal cancer.
4 Local recur-
rence rates were significantly reduced, and in subgroup
analyses, a distinct improvement in overall survival was
achieved in patients with optimal and good response to
applied CRT.
5
A benefit of a general application of adjuvant chemo-
therapy in individual patients remains unclear, and advices
for detection of patients with higher risk of cancer relapse
are imperatively needed.
6–9 Lymph node status after
preoperative CRT has repeatedly been described as a strong
prognostic factor in patients with locally advanced rectal
cancer.
10–12
Thus, the evaluation of an accurate nodal status is an
essential task for both surgeon and pathologist because
significant correlations between the number of retrieved
nodes and survival of patients have frequently been
demonstrated.
12–17 Several investigations have been pub-
lished within the last years showing that preoperative CRT
decreases the number of lymph nodes detected in the
surgical specimen.
18–20 Some authors report a consistent
remission of lymph nodes below the least number of 12
nodes, recommended by the International Union against
Cancer (UICC), or even a complete deletion of lymph
nodes in the surgical specimen.
21,22
We summarize results from 64 consecutive patients with
locally advanced rectal cancer from our institution. All
patients were participants of the randomized phase III
German Rectal Cancer Trial CAO/ARO/AIO-04 and
received standardized 5-FU-based long-term CRT, curative
surgical resection including TME, and extensive macro-
scopic and histopathological diagnostics.
The aim of this prospective study was to clarify the effects
of preoperative CRTon quantities of lymph nodes within the
mesorectal soft tissue compartment. Therefore, we meticu-
lously explored rectal cancer specimens with particular focus
on small nodes unlikely to be detected by standard manual
lymph node retrieval as predominately performed in the
retrospective analyses published in this subject.
Material and Methods
Sixty-four consecutive patients with resectable stage II/III
rectal adenocarcinoma located no more than 12 cm above
the anocutaneous verge and treated within the protocol of
the ongoing CAO/ARO/AIO-04 trial of the German Rectal
Cancer Study Group between October 2006 and September
2008 were analyzed prospectively.
All patients were medicated at the Department of
General and Visceral Surgery, University Medical Center
Göttingen, Germany.
Rigid rectoscopy with endorectal ultrasound (ERUS),
magnetic resonance imaging (MRI) of the pelvis, computed
tomography (CT) of the pelvis, abdomen, and thorax were
performed to confirm locally advanced tumor stage and to
exclude patients with evidence of distant metastases.
Except for one female patient with a squamous cell
carcinoma of the larynx more than 20 years earlier, no patient
had previous cancer or received cancer-related chemo- or
radiotherapy. There were no contraindications to CRT at the
time of staging in any patient. The trial was approved by the
Ethics Committee of the University of Göttingen.
Treatment
Sixty-four eligible patients (48 male and 16 female) with a
median age of 65 years (36–82 years) underwent standard-
ized preoperative CRT with a total irradiation dose of
50.4 Gy (in multiple three and four-field technique,
delivered in 28 fractions of 1.8 Gy) and a simultaneous 6-
week course of 5-FU-based chemotherapy.
Radical oncologic surgery was performed 6 weeks after
completion of preoperative treatment and actual clinical
restaging by experienced colorectal surgeons including
quality assessed TME in all cases.
Surgical procedures consisted of 46 (72%) low anterior
resections, 16 (25%) abdominoperineal resections, and two
(3%) discontinuous resections (Hartmann’s procedure).
Immediately after removal of the specimen, a perioper-
ative quality control of TME was performed by a surgeon
not involved in the actual surgical intervention.
This procedure consisted of methylene blue injection
into the inferior mesenteric artery and revealed smaller
surgery-related defects in pelvic fascia and mesorectal
surfaces by selective colorant escape.
Macroscopic and Histopathological Evaluation
After surgical quality control, the specimens were commit-
ted to the pathologist for macroscopic examination of
mesorectal surfaces according to a quality assessment
system based on the MERCURY criteria.
23 All 64 speci-
mens of this study were completely worked up by the same
gastrointestinal pathologist (H. R.).
Histopathological staging was realized according to the
tumor–node–metastasis (TNM) classification of the UICC
and comprised an evaluation of the circumferential resec-
tion margins (CRM) concerning tumor distance of ≤1m m
or tumor perforation.
24
The macroscopic work-up procedure consisted of a
ventral longitudinal opening of the specimen along the
rectal lumen excluding the tumor region and a fixation of
the draft-free needle-fixed specimen for at least 72 h in 5%
formalin solution.
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surface, the specimen was cut in consecutive transversal 5-
mm sectional slices, beginning at the distal resection
margin and comprising the region proximally of the tumor
at least up to the lateral vessel branching of the inferior
mesenteric artery.
The cross-sectional slices were re-divided into 2.5-mm
slices and completely paraffin embedded. Beside ypTNM
staging with assessment of the proximal, distal, and
circumferential resection margins, it was thus possible to
detect structures of microscopic dimension including any
residual tumor manifestation, i.e., very small and atrophic
lymph nodes below 0.1 cm in diameter with or without
micrometastases and isolated tumor cells, intra- or extra-
mural vascular and perineural invasion and mesorectal
tumor cell foci, which were presumably left behind after
CRT.
Within this procedure, fat clearance methods for detect-
ing lymph nodes were not used as the mesorectal soft tissue
was embedded completely.
Additionally, irradiation-induced tumor regression was
denoted on the basis of a semi-quantitative five-point
grading system according to established methods.
25,26
Microscopic Lymph Node Evaluation and Count
In order to evaluate the entire mesorectal soft tissue
compartment for available lymph nodes after preoperative
CRT, a complete paraffin-embedding of the rectal speci-
mens has been implemented. As unencapsulated lymphoid
aggregates with follicles are verifiable in pericolic and
perirectal tissue, histopathological criteria of a lymph node
have been defined prospectively. Only entirely encapsulated
lymphatic tissue with marginal sinus and at least residual
lymph follicles were—independently of size—counted as
lymph node. To prevent double-sectioning of individual—
particularly smaller (<2.5 mm)—nodes two optimal section
levels from each tissue block were examined consecutively
after cutting the block.
A median number of 147 standard sized tissue blocks
were examined per case (range, 119–213). Including 3 days
of formalin fixation, the median turn-around time from
surgical excision of the specimen to completion of final
diagnosis was 6 days.
Statistical Analysis
Correlations between numbers of detected mesorectal
lymph nodes and various patient- and tumor-related
clinicopathological findings were assessed by the function
cor. test of the statistical software R (version 2.8; www.r-
project.org).
The significance level was set to α=5% for all tests.
Results
Sixty-four surgical specimens with low and mid-third rectal
cancers (located within 12 cm from anal verge) were
investigated. Average tumor size (longitudinal dimension)
after treatment was 2.51 cm (0–8 cm; median, 2.5 cm), and
average tumor level was 6.4 cm from anal verge (0–12 cm;
median, 6.0 cm). Thirty tumors were located in the lower
third of the rectum (0–6 cm), 34 were positioned in the
mid-third (6–12 cm).
A histopathologically confirmed complete resection (R0
status) of proximal and distal resection margins was
achieved in all cases. Circumferential resection margins
(CRM) were free of vital tumor cells with a minimum
distance of ≥1 mm in each specimen. Seven patients
(11.7%) with no evidence of distant metastatic disease in
pretherapeutic CT scans presented with liver (six cases;
detected by intraoperative ultrasound) and peritoneal (one
case) metastases at the time of surgery. Due to their
consistent small size, the liver metastases might represent
systemic tumor progression during preoperative treatment
as well as misdiagnosis in initial clinical staging (Table 1).
Tumor regression parameters became apparent by T-level
downsizing (comparing cTand ypT) in 25 patients (39%). T-
level was decreased by one level in 11 patients (17.1%) and
by two or three levels in seven patients each (10.9%).
UICC downstaging (comparing cUICC and ypUICC)
was performed in 36 patients (56.3%). In 18 patients
(28.1%), the tumor stage was reduced by one, 11 patients
(17.1%) were downstaged by two, and finally, seven
patients (10.9%) were downstaged by three stages.
Tumor regression grading resulted in three patients
(4.6%) with low tumor regression (TRG 1). Fifty-three
patients (82.8%) had intermediate regression (TRG 2+3),
and eight patients (12.5%) presented with pathological
complete regression of the primary tumor (TRG 4).
Pathological quality assessment was performed according
to modified MERCURY criteria
23 respecting surgical stan-
dard of our institution and resulted in the following findings.
Thirty-six specimens (56.3%) showed optimal quality of
TME with no defects and smooth surfaces (grade 1). In 21
cases (32.8%), postsurgical mesorectal integrity was given
but with very little irregularities of the mesorectal surfaces
(grade 2), and seven (10.9%) specimens underwent TME
with focal defects and lacerations of mesorectal soft tissue
but, in all cases, without visible muscularis propria (grade 3).
An intra- or extramural vascular invasion was identified
in nine patients (14.1%). Perineural invasion appeared with
considerable frequency in 24 patients (37.5%) after preop-
erative CRT (Table 2).
A total number of 2,021 lymph nodes were recovered
(mean, 31.6 nodes per patient; range, 12–81; median, 30.0).
Twenty patients (31.3%) had persistent nodal metastases in
98 J Gastrointest Surg (2010) 14:96–103cumulative 53 lymph nodes. The mean number of involved
nodes was 2.65 per patient (range, 1–8 nodes; median, 1.0).
Among these 53 lymph node metastases, 15 manifested as
micrometastases (not larger than 0.2 cm). Three additional
patients (4.6%) showed evidence of isolated tumor cells
(ITC, not larger than 0.02 cm) in one lymph node each.
According to the current TNM classification, the latter were
classified as “ypN0” or “ypN0 (i+)” respectively, charac-
terizing ITC as cells without yet known specific metastatic
attributes.
27
Lymph node size including non-metastatic and meta-
static nodes was below 0.5 cm in all but one case. The
majority of nodes ranged between 0.1 and 0.2 cm.
One exceptional patient with mucinous differentiated
adenocarcinoma had lymph nodes ranging from 0.5 to 1 cm
without viable tumor cells but, instead, large mucinous
Feature Number of Patients Percent
n=64
Gender
Male 48 75
Female 16 25
Age (years)
Median 65
Range 36–82
Tumor Distance from Anal Verge (cm)
0–63 0 4 7
>6–12 34 53
cT stage
10 0
22 * 3
36 0 9 4
42 3
cN Stage
Positive 51 80
Negative 13 20
cUICC Stage
I0 0
II 13 20
III 51 80
IV 0 0
Neoadjuvant treatment
50.4 Gy+standard 5-FU 34 53
50.4 Gy + intensified 5-FU/oxaliplatin 30 47
Surgical procedure (including TME)
Low anterior resection 46 72
Abdominoperineal resection 16 25
Hartmann’s procedure 2 3
Resection status
R0 64 100
R1 0 0
Circumferential resection margin (CRM)
Negative 64 100
Positive 0 0
TME quality (modified Mercury criteria)
1 Optimal 36 56
2 Good 21 33
3 Moderate 7 11
Table 1 Clinicopathological
Findings
Patients had uN+ status accord-
ing cUICC III
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infiltration.
The detected mesorectal lymph nodes were unequally
distributed over the specimen.
The majority of 1,395 nodes (69%) were located
proximally to the tumor region along the trunk of the
superior rectal artery within the upper radiation field.
Four hundred forty-nine nodes (22%) were located
within the tumor region and therewith in the central
radiation field, and finally, 177 (9%) nodes could be
detected in the mesorectal tissue below the tumor region
and in the lower radiation field.
There was no significant correlation between the
numbers of detected mesorectal lymph nodes and patient-
dependent variables (gender and age). Tumor-related
variables (tumor size, ypTNM status, number of lymph
node metastases, histopathological tumor regression grade,
tumor differentiation, lymph and blood vessel invasion, and
perineural invasion) did also not affect the number of
available lymph nodes within the perirectal tissue (Table 3).
Due to the reduced lymph node size after preoperative
CRT, micrometastases (<0.2 cm) accounted for 28.3% of all
lymph node metastases. In detail, 30% of ypN+ patients
had exclusive micrometastatic involvement. Based on the
total study population, the proportion of patients with solely
micrometastases was 9.4% after CRT.
Under terms of extensive pathological work-up and
microscopic evaluation of the entire mesorectum, higher
numbers of identified lymph nodes per specimen were not
correlated with increased detection of nodal metastases. The
44 patients without nodal involvement had a median
number of 30 detected nodes, whereas patients with lymph
node metastases had 29.5 nodes. Interestingly, in patients
with solely micrometastatic involvement, the median
retrieval accounted for only 24.5 nodes.
In pretherapeutic staging (ERUS, CT, and MRI), 13
patients (20.3%) turned out to have no evidence of
mesorectal lymph node metastases (clinical stage II). In
pathological staging, altogether, four (31%) of 13 patients
with previous (clinical) stage II actually had ypN+ status
comprising four micrometastases in a single lymph node
each, indicating the potential incertitude of pretherapeutic
nodal staging.
Discussion
Lymph node status is currently the strongest prognostic
factor in rectal cancer after neoadjuvant CRT. A valid
statement concerning nodal involvement is of outstanding
importance for individual prognosis and further treatment
strategies of patients with locally advanced rectal cancer.
Reliable nodal staging of colorectal cancer requires a
certain number of detected and evaluated nodes and—as a
guideline, not as a precondition—lymphadenectomy should
ordinarily include 12 regional lymph nodes to validate pN0
status.
27 There are no particular recommendations
concerning effective lymph node retrieval in rectal cancer
specimens after preoperative CRT (ypN status) yet. Several
Table 2 Post-therapeutic Parameters
Feature Number of patients Percent*
n=64
Tumor size (cm)
Median 2.5
Range 0–8
Vascular invasion
Yes 9 14
No 55 86
Perineural Invasion
Yes 24 38
No 40 62
Tumor regression grading
00 0
13 5
22 0 3 1
33 3 5 2
48 1 3
ypT stage
08 1 3
17 1 1
29 1 4
33 6 5 6
44 6
ypN stage
04 4 6 9
11 5 2 3
25 8
ypM stage
05 7 8 9
17 1 1
ypUICC stage
08 1 3
I1 2 1 9
II 21 33
III 16 25
IV 7 11
T-level downsizing
Yes 25 39
No 39 61
UICC-downstaging
Yes 36 56
No 28 44
100 J Gastrointest Surg (2010) 14:96–103studies independently investigated the number of retrieved
lymph nodes in patients being treated with combined long-
term CRT and showed a continuous decrease in the number
of lymph nodes compared to non-irradiated specimens.
Mean numbers of detected nodes varied between 4 and 14
per specimen.
18–20,28 In our prospectively evaluated collec-
tive with standardized preoperative and surgical treatment
as well as pathological procedures, a mean number of 31.6
nodes were recovered per specimen.
Interpreting our results, we cannot disprove the assump-
tion that preoperative long-term CRT reduces the cumula-
tive number of lymph nodes within the rectal specimen,
although we detected surpassingly more mesorectal nodes
than any other investigation even without preoperatively
applied CRT.
10,13,18,19,21,29
This might be rationalized for one thing by standardized
and quality-controlled surgery and a high rate of optimally
performed TME within this study. The removal of the entire
mesorectal soft tissue compartment within its intact envelope
fascia not only ensures minimal local recurrence rates and
functional preservation of pelvic structuresbut also guaranties
a complete regional lymphadenctomy. Moreover, optimized
and extensive macro- and histopathological diagnostic proce-
dures are responsible for the detection of more than an
allegedly representative number of lymph nodes from a rectal
cancer specimen.
Under the terms of an extensive pathological work-up,
the rationale of nodal staging within this investigation has
been altered from evaluating a representative consensus-
agreed number of mesorectal nodes to evaluating the (near-)
total number of available rectal lymph nodes.
A significant reduction of lymph node count in rectal
cancer specimens has been reported after long-term
radiation (doses ranging from 45 to 50.4 Gy) with different
concomitant chemotherapy regimes
18–20,22,30 as well as
after short-term radiotherapy.
31,32 Only one single investiga-
tion did not find significant differences of mesorectal lymph
node retrieval in patients after neoadjuvant treatment com-
pared to patients who underwent primary surgical treatment.
However, in this study, altogether, only 17% of the study
population had neoadjuvant therapy comprising both long-
term 5-FU-based CRTas well as short-term radiation.
29
Perez et al. evaluated rectal specimens from 18 cadavers
without evidence of colorectal disease regarding number
and distribution of mesorectal lymph nodes. They found a
mean number of 5.7 nodes per specimen and concluded that
the absence of pathological alterations within the rectum
might cause lower lymph node count in contrast to other
investigations.
33
Anyway, concerning mesorectal lymph node numbers,
we did not find any correlation neither with patient-related
factors like gender and age nor tumor-related pathological
characteristics like individual stage or therapy-induced
tumor regression.
Additionally, our investigation indicates that neoadju-
vant CRT appears to have an important effect on mesorectal
lymph node size. We noticed that the majority of nodes
varied between 0.1 and 0.2 cm, which we consider to be a
consequence of applied CRT, in accordance with others
who also described a significant reduction of nodal
size.
32,34,35 Changes in morphology and function after
radiation of lymph nodes have also been described with
decreased numbers of CD4+ lymphocytes and dendritic
cells in paracortical areas of the irradiated nodes. This
might implicate a reduced immune and tumor suppressive
function as well as reduced mechanical filter function for
tumor cells.
36,37
It appears to us that radiation-related reduction of lymph
node size might be the main reason for a reputedly reduction
of lymph node numbers in irradiated specimens worked up
with conventional (manual) retrieval because of the apparent
difficulty to detect lymph nodes smaller than 0.2 cm.
Variable Correlation 95% Confidence Interval p value
Gender −0.11 −0.34; 0.12 0.34
Age −0.2 −0.41; 0.04 0.098
Surgical procedure 0.2 −0.03; 0.42 0.085
Tumor level 0.1 −0.13; 0.33 0.38
Tumor size 0.04 −0.2; 0.27 0.76
ypT −0.2 −0.41; 0.04 0.098
ypN 0 −0.23; 0.23 0.99
ypM −0.08 −0.3; 0.16 0.52
No. of nodal metastases 0.02 −0.21; 0.25 0.85
Tumor grading −0.2 −0.41; 0.03 0.089
Blood vessel invasion 0.07 −0.17; 0.29 0.59
Lymph vessel invasion 0.07 −0.16; 0.3 0.55
Perineural invasion −0.12 −0.34; 0.12 0.32
Table 3 Correlations Between
Lymph Node Numbers and Dif-
ferent Variables
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38 recognized lymph node size as an
independent prognostic indicator for survival in node-
negative rectal cancers after primary surgery. They sup-
posed small nodes, measuring <2 mm less likely to be
infiltrated and suggest a consideration of lymph node size
within the staging systems for rectal cancer.
As opposed to this, in 31% of our patients, lymph node
metastases have been detected, among these, 15 micro-
metastases (28.3%) in lymph nodes with constantly <0.3 cm.
Regarding other investigations using immunohistochemistry
to determine occult lymph node micrometastases in stage II
rectalcancersafterneoadjuvantCRT,thereisacomparatively
high incidence of micrometastases detected with convention-
ally hematoxylin–eosin staining in our collective.
39
Although their prognostic role has not been clarified,
finally, we consider them as important findings, which need
to be investigated further on to reveal individual tumor
biology and distant metastatic potential. We suppose an
appreciable number of mesorectal micrometastases in
lymph nodes below 0.5 cm not being detected by manual
lymph node recovery and standard pathological diagnostics.
Concerning the minimum number of lymph nodes
needed to stage patients with locally advanced rectal cancer,
statistical analyses indicated that the probability of detect-
ing a single lymph node metastasis increases with the
number of retrieved nodes and amounts to 46% when 18
nodes have been recovered.
40 This resulted in the recom-
mendation of finding smaller nodes ranging from 0.1 or
0.2 cm in diameter. Nevertheless, other investigations
revealed that more than 60% of institutions in the USA
fail to generally achieve the controversial benchmark of 12
lymph nodes per specimen.
41
Extensive pathological diagnostics with microscopic
evaluation of the entire lymph node containing mesorectal
compartment leads to obvious higher lymph node recovery
after preoperative CRT than conventional pathological
work-up. This has distinct clinical implications because
several investigations have shown the prognostic relevance
of enhanced lymph node retrieval in stage II colorectal and
rectal cancer patients.
13–15 Kim et al., who reported the
results of 900 node negative rectal cancer patients,
postulated a minimum number of 23 evaluated nodes to
stratify patients for low and high risk of cancer-specific
survival.
42 As nodal status—particularly after preoperative
CRT—is a major decision criterion for the need of adjuvant
treatment, it should be based on a stable diagnostic
fundament.
43
We are very well aware that the meticulous lymph node
evaluation in our study is hardly convertible in pathological
routine diagnostics in rectal cancer specimens. However, it
shows that adequate nodal staging is feasible after applied
CRT with consequently more than the consensual number
of 12 nodes per specimen. In summary, reliable lymph node
recovery emphasizes the role of the surgeon and especially
of the pathologist. Their role exceeds patient- and therapy-
dependent factors by far. These results of our evaluation are
supported by another large prospective investigation on
more than 7,000 colorectal specimens.
44
In conclusion, our study reveals that the diligence and
accuracy of the pathologist—beside the surgeons obligation
to supply high-quality TME specimens—is essential for
sufficient lymph node retrieval and valid nodal staging after
preoperative RCT.
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